|
"When the FDA changed its rule in 2023 to allow mail order abortion pills without the in-person doctor visit, women’s lives were put at risk,” said Susan Klein, Executive Director of Missouri Right to Life.
“Thousands of women have suffered serious health complications from Mifepristone. The FDA has admitted that it failed to adequately study the effects of the 2023 rule change on patient safety. The in-person doctor’s visit is essential to accurately determine the gestational age of the unborn child and to rule out ectopic pregnancies."
___________________
The following is from National Right to Life:
National Right to Life expressed deep disappointment today following the U.S. Supreme Court’s decision that allows loosened regulations surrounding the abortion drug mifepristone to remain in place while broader legal and scientific questions continue to be debated.
“This decision is deeply troubling because it leaves women exposed to powerful abortion drugs,” said Carol Tobias, president of National Right to Life. “Women facing unexpected pregnancies deserve real medical care and support, not a one-size-fits-all mail-order abortion system that minimizes risks and leaves women isolated during medical emergencies.”
Read more.
|